Hillsdale Investment Management Inc. Trims Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

Hillsdale Investment Management Inc. trimmed its position in Hims & Hers Health, Inc. (NYSE:HIMS) by 18.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 214,500 shares of the company’s stock after selling 48,100 shares during the period. Hillsdale Investment Management Inc. owned about 0.10% of Hims & Hers Health worth $5,187,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Crewe Advisors LLC purchased a new position in Hims & Hers Health in the 4th quarter valued at about $28,000. Raleigh Capital Management Inc. increased its stake in shares of Hims & Hers Health by 1,100.0% during the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 1,100 shares during the last quarter. Blume Capital Management Inc. increased its stake in shares of Hims & Hers Health by 100.0% during the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 600 shares during the last quarter. Smartleaf Asset Management LLC increased its stake in shares of Hims & Hers Health by 4,415.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock valued at $36,000 after acquiring an additional 1,413 shares during the last quarter. Finally, US Bancorp DE increased its stake in shares of Hims & Hers Health by 346.7% during the 4th quarter. US Bancorp DE now owns 1,943 shares of the company’s stock valued at $47,000 after acquiring an additional 1,508 shares during the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, CFO Oluyemi Okupe sold 4,213 shares of the stock in a transaction that occurred on Thursday, December 26th. The stock was sold at an average price of $29.98, for a total transaction of $126,305.74. Following the completion of the transaction, the chief financial officer now directly owns 128,365 shares in the company, valued at approximately $3,848,382.70. This represents a 3.18 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Soleil Boughton sold 4,152 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $60.69, for a total value of $251,984.88. Following the transaction, the insider now owns 157,345 shares in the company, valued at $9,549,268.05. This trade represents a 2.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 1,015,547 shares of company stock worth $36,146,450. 17.71% of the stock is currently owned by insiders.

Analysts Set New Price Targets

HIMS has been the subject of a number of research analyst reports. Piper Sandler upped their price objective on shares of Hims & Hers Health from $24.00 to $35.00 and gave the company a “neutral” rating in a research note on Tuesday, February 25th. Morgan Stanley downgraded shares of Hims & Hers Health from an “overweight” rating to an “equal weight” rating and upped their price objective for the company from $42.00 to $60.00 in a research note on Tuesday, February 18th. Citigroup reaffirmed a “sell” rating and set a $27.00 price objective on shares of Hims & Hers Health in a research note on Thursday, March 6th. BTIG Research assumed coverage on shares of Hims & Hers Health in a research report on Tuesday, January 7th. They set a “buy” rating and a $35.00 target price for the company. Finally, Bank of America increased their target price on shares of Hims & Hers Health from $21.00 to $22.00 and gave the stock an “underperform” rating in a research report on Tuesday. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, Hims & Hers Health has a consensus rating of “Hold” and a consensus price target of $37.31.

Hims & Hers Health Stock Up 5.8 %

Shares of NYSE:HIMS opened at $34.77 on Friday. Hims & Hers Health, Inc. has a 52-week low of $11.20 and a 52-week high of $72.98. The company has a 50 day moving average of $39.21 and a two-hundred day moving average of $28.69. The company has a market capitalization of $7.72 billion, a price-to-earnings ratio of 79.02 and a beta of 1.37.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. On average, equities analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.